deCODE Chemistry Initiates Chemical Development Collaboration with PolyMedix

Date Posted: Thursday, June 14, 2007

Print Email to a friend

deCODE chemistry has initiated a new chemical development service collaboration with PolyMedix, Inc.

Under the terms of the collaboration, deCODE’s process chemistry team will develop scalable synthetic routes for a number of products in PolyMedix’s pre-clinical pipeline. Following optimization of these production routes, deCODE will prepare larger-scale quantities of the compounds for pre-clinical development activities. These research activities build upon a successful process research program that was conducted by deCODE for PolyMedix under an earlier collaboration.

“We are very happy to be able to build upon the initial work we performed for PolyMedix, and enter into this broader collaborative relationship,” said Dr. David Zembower, Vice President of Chemistry at deCODE. “Our goal under this expanded collaboration is to help PolyMedix advance their compounds through the pre-clinical development pathway in the most efficient, economical manner possible.”

Further Information:

Related Products

deCODE Launches Fragments of Life™ Screening Technology
The library is intended to serve as an additional tool to enhance deCODE’s contract drug discovery services.

Related news from our archive

deCODE chemistry Initiates Chemical Development Collaboration with SGX Pharmaceuticals
SGX gains access to deCODE’s platform for chemical development including route optimization, production of toxicology lots and all associated analytical method development and validation.

deCODE Chemistry and FSMA Announce Extension of Research Agreement
The focus of the collaboration is to assess the pharmaceutical properties of lead candidates.